Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy

Background In patients receiving immune checkpoint inhibitor (ICI) therapy, acute kidney injury (AKI) is common, and can occur either from kidney injury unrelated to ICI use or from immune activation resulting in acute interstitial nephritis (AIN). In this study, we test the hypothesis that occurrence of AIN indicates a favorable treatment response to ICI therapy and therefore among patients who develop AKI while on ICI therapy, those with AIN will demonstrate greater survival compared with others with AKI. Methods In this observational cohort study, we included participants initiated on ICI therapy between 2013 and 2019. We tested the independent association of AKI and estimated AIN (eAIN) with mortality up to 1 year after therapy initiation as compared with those without AKI using time-varying Cox proportional hazard models controlling for demographics, comorbidities, cancer type, stage, and therapy, and baseline laboratory values. We defined eAIN as those with a predicted probability of AIN >90th percentile derived from a recently validated diagnostic model. Results Of 2207 patients initiated on ICIs, 617 (28%) died at 1 year and 549 (25%) developed AKI. AKI was independently associated with higher mortality (adjusted HR, 2.28 (95% CI 1.90 to 2.72)). Those AKI patients with eAIN had more severe AKI as reflected by a higher peak serum creatinine (3.3 (IQR 2.1–6.1) vs 1.4 (1.2–1.9) mg/dL, p<0.001) but exhibited lower mortality than those without eAIN in univariable analysis (HR 0.43 (95% CI 0.21 to 0.89)) and after adjusting for demographics, comorbidities, and cancer type and severity (adjusted HR 0.44 (95% CI 0.21 to 0.93)). Conclusion In patients treated with ICI, mortality was higher in those with AKI unrelated to ICI but lower in those where the underlying etiology was AIN. Future studies could evaluate the association of biopsy-proven or biomarker-proven AIN with mortality in those receiving ICI therapy.

[1]  N. LeBoeuf,et al.  Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. , 2022, JAMA dermatology.

[2]  L. Cantley,et al.  Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  D. Leaf,et al.  Acute kidney injury in patients treated with immune checkpoint inhibitors , 2021, Journal for ImmunoTherapy of Cancer.

[4]  Zhuoli Zhang,et al.  Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.

[5]  F. Wilson,et al.  Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19 , 2021, JAMA network open.

[6]  E. Felip,et al.  Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  M. Carini,et al.  Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors , 2021, Cancers.

[8]  L. Cantley,et al.  The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study , 2021, American Journal of Kidney Diseases.

[9]  L. Cantley,et al.  Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  K. Carey,et al.  Variation in Best Practice Measures in Patients With Severe Hospital-Acquired Acute Kidney Injury: A Multicenter Study. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Christopher T. Chan,et al.  Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes , 2020, Journal for immunotherapy of cancer.

[12]  M. Perazella,et al.  Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events , 2020, Kidney international reports.

[13]  Y. Kiyohara,et al.  Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan , 2020, The Journal of dermatology.

[14]  J. Berlin,et al.  Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. , 2020, The oncologist.

[15]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[16]  I. Glezerman,et al.  Kidney Complications of Immune Checkpoint Inhibitors: A Review. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  L. Gesualdo,et al.  The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma , 2019, Therapeutic advances in medical oncology.

[18]  Haiqun Lin,et al.  Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. , 2019, JCI insight.

[19]  C. Mascaux,et al.  Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. , 2019, Clinical lung cancer.

[20]  R. Luciano,et al.  Update on the Native Kidney Biopsy: Core Curriculum 2019. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  M. Suarez‐Almazor,et al.  Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience , 2019, Journal of Immunotherapy for Cancer.

[22]  M. Perazella,et al.  Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? , 2019, Kidney international.

[23]  K. Sayama,et al.  Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study. , 2019, Clinical therapeutics.

[24]  J. Herrmann,et al.  Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  R. Chiari,et al.  Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis , 2018, Journal of Cancer Research and Clinical Oncology.

[26]  Joni K. Evans,et al.  Risk of percutaneous renal biopsy of native kidneys in the evaluation of acute kidney injury , 2018, Clinical kidney journal.

[27]  J. Sugisaka,et al.  Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. , 2018, The oncologist.

[28]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[29]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[30]  Y. Koh,et al.  Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. , 2018, Lung cancer.

[31]  C. Parikh,et al.  Phenotyping of Acute Kidney Injury: Beyond Serum Creatinine. , 2018, Seminars in nephrology.

[32]  T. Morimoto,et al.  Early Immune‐Related Adverse Events and Association with Outcome in Advanced Non‐Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  M. Fujimoto,et al.  Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study , 2017, Cancer science.

[34]  D. Leaf,et al.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. , 2016, Kidney international.

[35]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.

[36]  M. Perazella,et al.  Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. , 2015, Iranian journal of kidney diseases.

[37]  M. Perazella.  Diagnosing drug-induced AIN in the hospitalized patient: A challenge for the clinician , 2014, Clinical nephrology.

[38]  W. Whittier,et al.  Percutaneous Renal Biopsy of Native Kidneys: A Single-Center Experience of 1,055 Biopsies , 2014, American Journal of Nephrology.

[39]  Notice , 2012, Kidney International Supplements.